(Washington, DC) – Judicial Watch announced today that it received 115 pages of records from the Department of Health and Human Services (HHS) revealing previously redacted locations of COVID-19 vaccine testing facilities in Shanghai, China. The Food and Drug Administration (FDA) claimed the testing facilities' name and locations were protected by the confidential commercial information exemption of the Freedom of Information Act (FOIA).
The records were obtained through a September 2021 FOIA lawsuit filed after the FDA, the Centers for Disease Control and Prevention and the National Institute for Allergy and Infectious Disease failed to respond to a June 7, 2021, FOIA request for all biodistribution studies and data for the COVID-19 vaccines (Judicial Watch v. U.S. Department of Health and Human Services (No. 1:21-cv-02418)).
The newly unredacted documents reveal the following Pfizer/BioNTech COVID-19 vaccine studies’ locations:
- A document with the filename “ s_r_IND 19736 0 105 2.6.5 pharmkintabulated-summary” identifies all in vitro metabolic stability studies of ALC-0315 and ALC-0159 (synthetic lipids in the vaccines) were conducted at Medicilon Preclinical Research LLC, a testing facility located in Shanghai, China. Studies within this record indicate work was done in August 2020.
- A document with the filename “s_r_IND 19736-0-253 Section 2.6.5 pharmkintabulated-summary” identifies that all in vitro metabolic stability studies of ALC-0315 and ALC-0159 were conducted at Medicilon Preclinical Research LLC, a testing facility located in Shanghai, China. Studies within this record indicate work was done in August 2020.
Additionally, Study 18350 was conducted at a Charles River testing facility in Tranent, UK
- A document with the filename “s_pharmkin-tabulated-summary.pdf” notes that all in vitro metabolic stability studies of ALC-0315 and ALC-0159 were conducted at Medicilon Preclinical Research LLC, a testing facility located in “Shanghai, China.” Studies within this record indicate work was done in August 2020.
The document adds that Study 18350 was conducted at a Charles River testing facility in Tranent, UK.
- A document titled “FINAL REPORT” with the filename “s_r_185350.pdf” and the logo, “Charles River” lists the TESTING FACILITY as “Charles River Laboratories Edinburgh Ltd. Elphinstone Research Centre Tranent, East Lothian EH33 2NE, UK” Studies within this record indicate the work was conducted in July 2020.
“The Biden administration’s stonewalling and shell games about the COVID vaccines further undermine public confidence in these controversial drugs,” stated Judicial Watch President Tom Fitton. “Americans are now going to want to know why the Biden operation tried to hide COVID vaccine ties to China!”
This is part of Judicial Watch’s ongoing investigation into the US Government’s handling of the COVID-19 pandemic.
In July 2022, National Institutes of Health (NIH) records revealed an FBI “inquiry” into the NIH’s controversial bat coronavirus grant tied to the Wuhan Institute of Virology. The records also show National Institute of Allergy and Infectious Diseases (NIAID) officials were concerned about “gain-of-function” research in China’s Wuhan Institute of Virology in 2016. The Fauci agency was also concerned about EcoHealth Alliance’s lack of compliance with reporting rules and use of gain-of-function research in the NIH-funded research involving bat coronaviruses in Wuhan, China.
Previous disclosures from this lawsuit include:
- HHS records revealed that from 2014 to 2019, $826,277 was given to the Wuhan Institute of Virology for bat coronavirus research by the NIAID.
- NIAID records showed that it gave nine China-related grants to EcoHealth Alliance to research coronavirus emergence in bats and was the NIH’s top issuer of grants to the Wuhan lab itself. The records also included an email from the vice director of the Wuhan Lab asking an NIH official for help finding disinfectants for decontamination of airtight suits and indoor surfaces.
- HHS records included an “urgent for Dr. Fauci ” email chain, citing ties between the Wuhan lab and the taxpayer-funded EcoHealth Alliance. The government emails also reported that the foundation of U.S. billionaire Bill Gates worked closely with the Chinese government to pave the way for Chinese-produced medications to be sold outside China and help “raise China’s voice of governance by placing representatives from China on important international counsels as high level commitment from China.”
- HHS records included a grant application for research involving the coronavirus that describes “gain-of-function” research involving RNA extractions from bats, experiments on viruses, attempts to develop a chimeric virus and efforts to manipulate the full-length bat SARSr-CoV WIV1 strain molecular clone genetically.
- HHS records showed the State Department and NIAID knew immediately in January 2020 that China was withholding COVID data, which was hindering risk assessment and response by public health officials.
Through FOIA, Judicial Watch has uncovered a substantial amount of information about other important COVID-19 issues:
- May 2022: University of Texas Medical Branch (UTMB) records show the former director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB), Dr. James W. Le Duc warned Chinese researchers at the Wuhan Institute of Virology of potential investigations into the COVID issue by Congress.
- May 2022: HHS records regarding biodistribution studies and related data for the COVID-19 vaccines show a key component of the vaccines developed by Pfizer/BioNTech, lipid nanoparticles (LNPs), were found outside the injection site, mainly the liver, adrenal glands, spleen and ovaries of test animals, eight to 48 hours after injection.
- April 2022: Records from the Federal Select Agent Program (FSAP) reveal safety lapses and violations at U.S. biosafety laboratories that conduct research on dangerous agents and toxins.
- March 2022: HHS records include emails between National Institutes of Health (NIH) then-Director Francis Collins and Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), about hydroxychloroquine and COVID-19.
- March 2021: HHS records show that NIH officials tailored confidentiality forms to China’s terms and that the World Health Organization (WHO) conducted an unreleased, “strictly confidential” COVID-19 epidemiological analysis in January 2020.
- October 2020: Fauci emails include his approval of a press release supportive of China’s response to the 2019 novel coronavirus.
- An October 2021 lawsuit uncovered that over a 10-year period, Fauci and others at NIH received more than $350 million in secretive “royalty” payments from drug companies and other third parties.